Unlock instant, AI-driven research and patent intelligence for your innovation.

Bridged bicyclic serine protease inhibitors

A cycloalkyl and heterocyclic group technology, which can be applied in the fields of peptide/protein components, medical preparations containing active ingredients, antiviral agents, etc., can solve the problems of unclear prospects for effective anti-HCV vaccines

Inactive Publication Date: 2004-09-01
VERTEX PHARMA INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, the prospects for an effective vaccine against HCV remain uncertain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bridged bicyclic serine protease inhibitors
  • Bridged bicyclic serine protease inhibitors
  • Bridged bicyclic serine protease inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0406] Ethyl (1S, 3S, 4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylate (1) (e.g. n=0, m=0; each R 20 =H) see process 1

[0407] To a stirred solution of, for example, 50% ethyl glyoxylate in toluene (23ml, 0.112mol, 1.0eq) in 600ml anhydrous DCM at 0°C was added (R)-methylbenzylamine (15ml, 0.118mol, 1.05eq), the solution contained 27g 4A molecular sieves. The reaction mixture was stirred at 0°C for 1 hour, then cooled to -78°C. The following three reagents were added sequentially with 5 min intervals between each addition: TFA (9.08ml, 0.118mmol, 1.05eq), boron trifluoride etherate (14.93ml, 0.118mol, 1.05eq), and e.g. Diene (16.37ml, 0.146mol, 1.3eq). The reaction mixture was stirred at -78°C for 5 hours and then allowed to warm to room temperature. The molecular sieves were separated and the reaction mixture was carefully washed with saturated aqueous sodium bicarbonate (250ml), brine (250ml) and dried over magnesium sulfate. Concentration and pu...

Embodiment 2

[0409] Ethyl (1S, 3S, 4R)-2-azabicyclo[2.2.1]heptane-3-carboxylate (2) (e.g. o=1, m=0; each R 20 =H)

[0410] Aza Diels-Alder adduct 1(23.5g; 0.086mol) was dissolved in 200ml absolute ethanol, for example, Pd-C 10% (600mg) was added. The mixture was stirred under hydrogen (55 psi) at room temperature for 16 hours. Filtration through a Celite pad (or nylon / carbon fiber combination) and concentration gave 14.2 g 2 (97%), a light yellow oil, used directly in the next step. The compound was identified by NMR.

Embodiment 3

[0412] (1S, 3S, 4R)-2-benzoylazabicyclo[2.2.1]heptane-3-carboxylic acid 3 (for example o=1, m=0, each R 20 =H)

[0413] To, for example, a mixture of 1N NaOH (71ml, 0.143mol, 3.5eq) and 71ml of water was added amino ester 2 (3.45g, 0.0204mol, 1.0eq) and stirred at room temperature for 4 hours (TLC monitoring w / EtOAc with 5% TEA mixture). When the saponification is complete, add 100ml of acetone and lower the temperature to 0°C. A solution of benzyl chloroformate (3.5ml, 0.0244mol, 1.2eq) in 40ml of acetone was added slowly and the reaction mixture was stirred at room temperature for 16 hours maintaining the pH at about 9-10 with 1N NaOH. Acetone was removed and 200ml of water was added. The aqueous phase was washed with ether (3 x 200ml) and acidified to pH 2-3 with 2N HCl. The product was extracted with EtOAc (3 x 250ml), dried (Na 2 SO 4 ), concentrated in vacuo to afford 3.85 g (70%) of amino acid 3. This compound was used directly in the next step. The compound was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

Description

technical field [0001] The present invention relates to peptidomimetic compounds which inhibit the activity of serine proteases, more specifically the activity of the hepatitis C virus NS3-NS4A protease. They work by interfering with the life cycle of the hepatitis C virus and are also used as antiviral agents. The compounds of the invention are characterized by a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds for ex vivo use or administration to patients suffering from HCV infection. The invention also relates to a method of treating HCV infection in a patient by administering a composition comprising a compound of the invention. Background technique [0002] Hepatitis C virus (HCV) infection is an urgent human medical problem. HCV is recognized as the cause of most non-A, non-B hepatitis cases, with an estimated 3% seroprevalence in the global population [A.Alberti et.al., "Natural History of Hepatiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/13A61K31/7052A61K38/00A61K38/21A61P31/12A61P31/14A61P43/00C07K5/103C07K5/107C07K5/11C07K5/117C07K7/02C07K7/06
CPCC07K5/1008C07K5/1016C07K7/02A61K38/00C07K5/1024C07K5/1019A61P31/12A61P31/14A61P43/00C07D471/08
Inventor L·法莫J·皮特里克R·伯尔尼L·库尔特尼J·范德里
Owner VERTEX PHARMA INC